Lv32
326 积分 2024-06-03 加入
The impact of enzyme replacement therapy on the oral health manifestations of hypophosphatasia among children: a scoping review
3天前
已完结
Safety and efficacy of ravulizumab in patients with NMOSD previously treated with rituximab: A post hoc analysis of the CHAMPION-NMOSD trial
5天前
已关闭
Safety and efficacy of the selective tyrosine kinase 2/Janus kinase 1 inhibitor TLL-018 in moderate-to-severe plaque psoriasis: a phase Ib, randomized, double-blind, placebo-controlled study
7天前
已完结
Safety and efficacy of the selective tyrosine kinase 2/Janus kinase 1 inhibitor TLL-018 in moderate to severe chronic spontaneous urticaria patients with inadequate response to H1 antihistamines: a phase Ib, randomized, double-blind, placebo-controlled pilot study
8天前
已完结
Overall Survival with Amivantamab–Lazertinib in EGFR-Mutated Advanced NSCLC
14天前
已完结
Survival with Amivantamab–Lazertinib in EGFR-Mutated NSCLC
14天前
已关闭
Amivantamab plus Lazertinib in Previously Untreated EGFR -Mutated Advanced NSCLC
14天前
已关闭
Amivantamab plus Lazertinib in Previously Untreated EGFR -Mutated Advanced NSCLC
14天前
已完结
Amivantamab plus Lazertinib in Previously Untreated EGFR -Mutated Advanced NSCLC
17天前
已完结
Amivantamab plus Lazertinib in Previously Untreated EGFR -Mutated Advanced NSCLC
17天前
已完结
皖公网安备34019202002308
